Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies.
Shuangcheng LiTianci WangXinghui XiaoXiaodong ZhengHaoyu SunRui SunHongdi MaZhigang TianXiaohu ZhengPublished in: Cancer biology & medicine (2024)
These results propose CD300A as a potential target for invigorating NK cell-based treatments against HMs.